Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30226782 | 1.00 | CA12 (0.51) | CA12CA9GSK3BALDH1A1NPSR1 | |
| SCHEMBL1273994 | 1.00 | CA12 (0.51) | CA12CA9GSK3BALDH1A1NPSR1 | |
| SCHEMBL30226990 | 1.00 | CA12 (0.51) | CA12CA9GSK3BALDH1A1NPSR1 | |
| SCHEMBL9659771 | 1.00 | CA12 (0.51) | CA12CA9GSK3BALDH1A1NPSR1 | |
| SCHEMBL1274668 | 0.83 | CA12 (0.51) | CA12CA9GSK3BALDH1A1NPSR1 | |
| SCHEMBL22216426 | 0.83 | CA12 (0.51) | CA12CA9GSK3BALDH1A1NPSR1 | |
| SCHEMBL22216274 | 0.83 | CA12 (0.51) | CA12CA9GSK3BALDH1A1NPSR1 | |
| SCHEMBL22216369 | 0.83 | ALDH1A1 (0.53) | CA12CA9GSK3BALDH1A1NPSR1 | |
| SCHEMBL12934074 | 0.83 | CA12 (0.51) | CA12CA9GSK3BALDH1A1NPSR1 | |
| SCHEMBL1274667 | 0.83 | CA12 (0.51) | CA12CA9GSK3BALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172392-A1 | AMINE-BASED AND AMIDE-BASED INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) ENZYME ACTIVITY AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT OF DISEASES | SALTER-CID LUISA M (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172392-A1 | AMINE-BASED AND AMIDE-BASED INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) ENZYME ACTIVITY AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT OF DISEASES | SALTER-CID LUISA M (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172392-A1 | AMINE-BASED AND AMIDE-BASED INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) ENZYME ACTIVITY AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT OF DISEASES | SALTER-CID LUISA M (US) | 2012-07-05 | — | — | US | disclosed |
| EP-2283833-A2 | Amines and amides for the treatment of diseases | LA JOLLA PHARMACEUTICAL CO. (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20070078157-A1 | Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO)enzyme activity and VAP-1 mediated adhesion useful for treatment of diseases | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070078157-A1 | Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO)enzyme activity and VAP-1 mediated adhesion useful for treatment of diseases | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070078157-A1 | Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO)enzyme activity and VAP-1 mediated adhesion useful for treatment of diseases | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2007-04-05 | — | — | US | disclosed |
| EP-1732531-A2 | AMINES AND AMIDES FOR THE TREATMENT OF DISEASES | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060025438-A1 | Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO) enzyne activity and VAP-1 mediated adhesion useful for treatment of diseases | LA JOLLA PHARMACEUTICAL COMPANY | 2006-02-02 | — | — | US | disclosed |
| WO-2005082343-A2 | AMINES AND AMIDES FOR THE TREATMENT OF DISEASES | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
| EP-0168013-B1 | FLUOROALLYLAMINE DERIVATIVES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-03-02 | — | — | EP | disclosed |
| US-4699928-A | ANTIDEPRESSANTS, TREATMENT OF PARKINSON'S DISEASE | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-10-13 | — | — | US | disclosed |
| EP-0168013-A1 | Fluoroallylamine derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1986-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078157-A1 | Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO)enzyme activity and VAP-1 mediated adhesion useful for treatment of diseases | VCAM1, AOC2, AOC1 | CA12 4019/4885CA9 3011/4885GSK3B 4620/4885 |
| US-20120172392-A1 | AMINE-BASED AND AMIDE-BASED INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) ENZYME ACTIVITY AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT OF DISEASES | VCAM1, AOC2, AOC1 | CA12 4019/4885CA9 3011/4885GSK3B 4620/4885 |
| US-20060025438-A1 | Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO) enzyne activity and VAP-1 mediated adhesion useful for treatment of diseases | VCAM1, AOC3, AOC2 | CA12 4419/4885CA9 4423/4885GSK3B 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.